摘要
目的:评价大剂量辛伐他汀40mg/d对国人调脂作用的有效性和安全性。方法:从中国生物医学数据库(CBMdisc)、中国期刊网全文数据库、维普全文电子期刊和OVID中检索2001年至2007年的相关文献,主要入选标准:(1)研究内容为国内辛伐他汀40mg/d的临床应用;(2)研究对象为心血管疾病、糖尿病、高脂血症病人;(3)研究观察时间不少于2个月;(4)分别记录用药前后血脂的变化及样本量的大小;(5)数据为计量资料。比较应用辛伐他汀40mg/d前后血脂的变化,并利用Rev-Man4.2对数据进行Meta分析,同时对其安全性作出评价。结果:11项研究共517例病人入选,经辛伐他汀40mg/d治疗2个月后LDL-C平均降低1.54mmol/L,TC平均降低2.25mmol/L,HDL-C平均升高0.16mmol/L(P均<0.00001)。主要不良反应为恶心、纳差、腹胀腹痛,共15例;轻度丙氨酸氨基转换酶(ALT)升高11例、轻度肌酸激酶(CK)升高8例,肌肉酸痛2例。均未出现严重的不良反应。结论:辛伐他汀40mg/d在国内的临床调脂治疗中疗效和安全性均较好。
Objective：To evaluate the efficiency and safety of simvastatin 40mg/d treatment in Chinese people. Methods：Trials were identified through searching of CBMdisc, CNKI, Weipu and OVID （from year 2001 to 2007） and hand-searching of cross references from original articles and reviews. The major criteria for inclusion were： （1） Clinical trials of simvastatin 40mg/d in Chinese. （2） Patients with cardiovascular disease or diabetes mellitus or hyperlipoidemia. （3） Lasting for at least 2 months. （4） Providing the detail data of the simvastatin therapy （both before and after）. （5） The outcomes were putted in measurement data. Then compared the level of cholesterol before and after the therapy and conducted a meta analysis with Revman 4.2. Results：A totel of 11 trials （n = 517） were eligible. Averagely, LDL-C were reduced 1.54mmol/L, TC were reduced 2.25mmol/L, HDL-C were increased 0. 16mmol/L（P〈0. 00001 ）. Main adverse effects include nausea, abdominal pain, diarrhea （n= 15）, slightly increase in ALT（n= 11）, in CK（n= 8） and myosalgia （n = 2）. No severe side effects had occurred. Conclusion： Simvastatin 40mg/d can effectively lower the level of LDL-C, TC and increase HDL-C in Chinese with good safety.
出处
《国际心血管病杂志》
2008年第2期117-120,123,共5页
International Journal of Cardiovascular Disease
